NCT02787369 2026-01-07
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)